Filtered By:
Condition: Heart Valve Disease

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 554 results found since Jan 2013.

SAPIEN 3 improves 30-day outcomes for major endpoints, study suggests
The SAPIEN 3 heart valve demonstrated lower death, stroke and paravalvular leak rates than earlier generation devices in patients at high risk for surgery and showed encouraging results in intermediate-risk patients, according to new research.
Source: ScienceDaily Headlines - March 16, 2015 Category: Science Source Type: news

Valvuloplasty with a paclitaxel-eluting balloon prevents restenosis in an experimental animal model of aortic stenosis.
CONCLUSION: Use of a paclitaxel-eluting valvuloplasty balloon in an animal model of AS resulted in attenuated restenosis, secondary to decrease in valve proliferation and calcification. PMID: 25803975 [PubMed - in process]
Source: Journal of Heart Valve Disease - March 26, 2015 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

'Paradoxical' low-flow, low-gradient severe aortic valve stenosis: an entity with limited improvement following transcatheter aortic valve implantation.
CONCLUSION: Patients with PLF-LG-AS may represent a subgroup with a worse clinical outcome after TAVI. PMID: 25803970 [PubMed - in process]
Source: Journal of Heart Valve Disease - March 26, 2015 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

Contraindications to Anticoagulation Therapy and Eligibility for Novel Anticoagulants in Older Patients With Atrial Fibrillation
ConclusionsOlder adults with atrial fibrillation rarely have absolute contraindications to oral anticoagulation therapy. Among patients without contraindications, most appeared to be eligible for any anticoagulant, and relatively high‐risk features appeared not to influence warfarin use.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - April 1, 2015 Category: Cardiology Authors: Benjamin A. Steinberg, Melissa A. Greiner, Bradley G. Hammill, Lesley H. Curtis, Emelia J. Benjamin, Susan R. Heckbert, Jonathan P. Piccini Tags: Original Research Article Source Type: research

John Glenn Says Evolution Should Be Taught In Schools
COLUMBUS, Ohio (AP) — John Glenn, who declared as a 77-year-old in a news conference from space that "to look out at this kind of creation out here and not believe in God is to me impossible," says facts about scientific discovery should be taught in schools — and that includes evolution. The astronaut, now 93 with fading eyesight and hearing, told The Associated Press in a recent interview that he sees no contradiction between believing in God and believing in evolution. "I don't see that I'm any less religious by the fact that I can appreciate the fact that science just records that we change with evolution and tim...
Source: Science - The Huffington Post - May 20, 2015 Category: Science Source Type: news

Thirty-day VARC-2 and performance data of a new self-expanding transcatheter aortic heart valve.
CONCLUSIONS: In this first-in-human study, the feasibility of implantation of the BIOVALVE system and its re-sheathing functionality was demonstrated, and short-term safety data were encouraging. Larger studies are required to confirm the performance of the device. PMID: 25983028 [PubMed - as supplied by publisher]
Source: EuroIntervention - May 21, 2015 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research

The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial
In conclusion, more frequent PST improved TTR and reduced the proportion of poorly managed patients.
Source: Journal of Thrombosis and Thrombolysis - May 29, 2015 Category: Hematology Source Type: research

TAVI: Good early data for Keystone Heart’s TriGuard
Data from a trial of Keystone Heart‘s TriGuard anti-stroke device showed a lower rate of neurologic deficits after transcatheter aortic valve implantation, according to research presented last month at EuroPCR 2015 in Paris. The 85-patient Deflect 3 study found that TAVI patients treated with the Israeli company’s TriGuard, which is designed to allow blood to […] The post TAVI: Good early data for Keystone Heart’s TriGuard appeared first on MassDevice.
Source: Mass Device - June 2, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Neurological Replacement Heart Valves Keystone Heart TAVI Source Type: news

TAVI: Boston Scientific’s Lotus valve tops Medtronic’s CoreValve – study
Data from a study of Boston Scientific‘s (NYSE:BSX) Lotus Valve showed a greater device success rate than Medtronic‘s (NYSE:MDT) CoreValve in high-risk transcatheter aortic valve replacement patients. The single-center, non-randomized study, published this month in the journal JACC: Cardiovascular Interventions, compared outcomes from 50 high-risk TAVI patients treated with the Lotus valve and 50 similar patients treated with Medtronic’s self-expanding CoreValve device. Success rates were higher at 30 days in the Lotus group, at 84%, versus 64% with CoreValve, according to the study.  These results...
Source: Mass Device - June 17, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Clinical Trials Replacement Heart Valves Boston Scientific JACC: Cardiovascular Interventions medtronic Source Type: news

Low Incidence of Paravalvular Leakage With the Balloon-Expandable Sapien 3 Transcatheter Heart Valve
Conclusions The present study shows excellent clinical and hemodynamic outcomes of high-risk transapical valve replacement patients treated with the new S3 THV. The S3 THV shows a low incidence of postoperative aortic regurgitation, with 98% presenting with less than mild aortic regurgitation.
Source: The Annals of Thoracic Surgery - June 24, 2015 Category: Cardiovascular & Thoracic Surgery Source Type: research

Low Incidence of Paravalvular Leakage With the Balloon-Expandable Sapien 3 Transcatheter Heart Valve.
CONCLUSIONS: The present study shows excellent clinical and hemodynamic outcomes of high-risk transapical valve replacement patients treated with the new S3 THV. The S3 THV shows a low incidence of postoperative aortic regurgitation, with 98% presenting with less than mild aortic regurgitation. PMID: 26117587 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - June 24, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Wendt D, Al-Rashid F, Kahlert P, Eißmann M, El-Chilali K, Janosi A, Pasa S, Tsagakis K, Liakopoulos O, Erbel R, Jakob H, Thielmann M Tags: Ann Thorac Surg Source Type: research

How to define valvular atrial fibrillation?
Abstract Atrial fibrillation (AF) confers a substantial risk of stroke. Recent trials comparing vitamin K antagonists (VKAs) with non-vitamin K antagonist oral anticoagulants (NOACs) in AF were performed among patients with so-called "non-valvular" AF. The distinction between "valvular" and "non-valvular" AF remains a matter of debate. Currently, "valvular AF" refers to patients with mitral stenosis or artificial heart valves (and valve repair in North American guidelines only), and should be treated with VKAs. Valvular heart diseases, such as mitral regurgitation, aortic stenosis (AS) and aortic insufficiency, do...
Source: Archives of Cardiovascular Diseases - July 13, 2015 Category: Cardiology Authors: Fauchier L, Philippart R, Clementy N, Bourguignon T, Angoulvant D, Ivanes F, Babuty D, Bernard A Tags: Arch Cardiovasc Dis Source Type: research

Clinical Value of Ankle-Brachial Index in Asymptomatic Aortic Stenosis Patients.
CONCLUSION: Among asymptomatic AS patients, 35.8% had an abnormal ABI and this was related to previous diabetes. These patients walked less in the 6MWT but did not have a worse prognosis at follow up. PMID: 26204678 [PubMed - in process]
Source: Journal of Heart Valve Disease - July 25, 2015 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

Study: Edwards’ Sapien and Medtronic’s CoreValve outcomes are similar
A new study published in the Journal of the American College of Cardiology found that patients treated with Edwards Lifesciences‘s (NYSE:EW) and Medtronic‘s (NYSE:MDT) CoreValve showed similar results after 1 year. The 241-patient trial examined high-risk patients with symptomatic severe aortic stenosis 1 year after being treated with either Edwards’s Sapien balloon expanding or Medtronic’ self-expanding transcatheter heart valve. The rates of all-cause death and cardiovascular death were not statistically different between the groups, with a 3-5% difference between the 2 devices, according to the ...
Source: Mass Device - August 11, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Edwards Lifesciences medtronic Source Type: news

MassDevice.com +3 | The top 3 medtech stories for August 10, 2015
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.   3. NDC closes Interface Catheter buy, rebrands as Confluent Nitinol Devices & Components said it closed its acquisition of Interface Catheter Solutions and announced it will rebrand the new combined company as Confluent Medical Technologies. Confluent Medical will leverage both NDC and Interf...
Source: Mass Device - August 10, 2015 Category: Medical Equipment Authors: MassDevice Tags: Blog Plus 3 Source Type: news